Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity
Glen Huang, Alex J. Kovalic, Christopher J. Graber
Abstract
T he incidence of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread rapidly globally; as of March 29, 2020, 670,000 cases had been confirmed worldwide (1). COVID-19 is typically a pulmonary infection that can range from mild illness to acute respiratory distress syndrome and multiple organ failure; however, other symptoms such as myalgias and anorexia have been noted (2). Although many ongoing studies are investigating measurement of proinflammatory cytokines and other biomarkers as a way to prognosticate infection severity, we investigated use of 2 easily obtained predictors: lymphopenia and leukocytosis (3).
Topics & Concepts
LeukocytosisDiseaseCoronavirusMedicineSeverity of illnessCoronavirus disease 2019 (COVID-19)ImmunologyLymphocyteInternal medicineNeutrophil to lymphocyte ratioIntensive care medicineInfectious disease (medical specialty)COVID-19 Clinical Research StudiesInflammatory Biomarkers in Disease PrognosisSepsis Diagnosis and Treatment